A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure With Reduced Ejection Fraction and Decreased Exercise Tolerance
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 31 Dec 2018
At a glance
- Drugs Omecamtiv mecarbil (Primary)
- Indications Heart failure
- Focus Registrational; Therapeutic Use
- Acronyms METEORIC-HF
- Sponsors Amgen
- 14 Dec 2018 Planned initiation date changed from 7 Dec 2018 to 21 Jan 2019.
- 28 Nov 2018 Status changed from planning to not yet recruiting.
- 16 Oct 2018 According to a Cytokinetics media release, company has announced trial design and this trial is this trial in expected to start by the end of 2018.